Enovis (ENOV) Projected to Post Quarterly Earnings on Thursday

Enovis (NYSE:ENOV) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of $0.7670 per share and revenue of $557.15 million for the quarter. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. The firm had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. Enovis’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.79 EPS. On average, analysts expect Enovis to post $3.15 EPS for the current fiscal year and $3.08 EPS for the next fiscal year.

Enovis Stock Performance

Shares of ENOV opened at $21.85 on Thursday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The stock has a market capitalization of $1.26 billion, a P/E ratio of -1.13 and a beta of 1.37. Enovis has a 1 year low of $16.70 and a 1 year high of $33.13. The company’s fifty day moving average is $20.22 and its two-hundred day moving average is $23.15.

Insider Transactions at Enovis

In other news, insider Oliver Engert bought 5,140 shares of Enovis stock in a transaction on Thursday, September 3rd. The shares were bought at an average price of $19.46 per share, with a total value of $100,024.40. Following the acquisition, the insider directly owned 61,238 shares in the company, valued at approximately $1,191,691.48. This represents a 9.16% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Damien Mcdonald acquired 13,035 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was acquired at an average cost of $19.15 per share, with a total value of $249,620.25. Following the acquisition, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 23,293 shares of company stock worth $449,599. 2.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ENOV has been the topic of several recent research reports. Wells Fargo & Company decreased their price objective on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 2nd. Evercore set a $32.00 price target on shares of Enovis in a report on Monday, July 6th. UBS Group reiterated a “buy” rating and issued a $44.00 price target on shares of Enovis in a research report on Monday, October 5th. Needham & Company LLC dropped their price objective on shares of Enovis from $52.00 to $34.00 and set a “buy” rating for the company in a research note on Monday, October 12th. Finally, Canaccord Genuity Group reduced their target price on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, August 17th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.25.

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.